RxDoctor Payments Data

Janine Chamberlin, MD

Family Medicine · Brea, CANPI 1225210016

Payments from drug & device makers

$340in general payments, 2019–2025

Across 15 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$83
  • Pfizer$73
  • GSK$64
  • Lilly USA, LLC$53
  • Inari Medical, Inc.$27
  • Hologic Sales And Service, LLC$22
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)3$83
Pfizer4$73
GSK3$64
Lilly USA, LLC2$53
Inari Medical, Inc.1$27
Hologic Sales And Service, LLC1$22
Novo Nordisk1$19

How this compares

$340 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$56,184
Medicare patients
201
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$87,505
JardianceEmpagliflozin67$78,141
MounjaroTirzepatide23$40,115
JanuviaSitagliptin Phosphate32$39,125
EliquisApixaban39$38,575
ProliaDenosumab17$29,843
Nurtec OdtRimegepant Sulfate18$29,578
JanumetSitagliptin Phos/Metformin Hcl15$23,196
TrulicityDulaglutide15$19,078
Repatha SureclickEvolocumab15$17,412
NamzaricMemantine Hcl/Donepezil Hcl11$16,946
UbrelvyUbrogepant14$14,231
TradjentaLinagliptin13$11,836
RestasisCyclosporine11$11,097
Breo ElliptaFluticasone/Vilanterol16$8,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$87,50574 claims
PfizerEliquis, Nurtec Odt, Premarin$73$74,52573 claims
Lilly USA, LLCMounjaro, Trulicity$53$59,19238 claims
AmgenProlia$83$29,84317 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$64$19,85538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →